Last reviewed · How we verify
NCT04687267
Conservative Management of CIN2 Lesions and Biomarkers Evaluation
trial in CIN2 in 319 participants. Completed in 31 December 2022.
31 October 2021
Quick facts
| Lead sponsor | Istituto Oncologico Veneto IRCCS |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 319 |
| Start date | 15 April 2019 |
| Primary completion | 31 October 2021 |
| Estimated completion | 31 December 2022 |
| Sites | 4 locations across Italy |
Conditions studied
- CIN2 — all drugs for CIN2 →
Sponsor
Istituto Oncologico Veneto IRCCS — full company profile →
Who can join
Adults 25 to 45, female only, with CIN2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prospective study including women aged 25-45 years, adherent to the cervical screening program of four different centers of the Veneto region, with a diagnosis of CIN2 lesion. After enrollment according to predefined criteria, and informed consent to participate, the CIN2 lesions are managed by follow-up; cases with progressive lesions will be treated immediately, cases with CIN2 persistence for more than 12 months will be treated as well. Viral, molecular and immunocytochemical biomarkers will be studied, and evaluated in relation to the clinical outcome.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Predictive biomarkers for regression in women undergoing active surveillance for cervical intraepithelial neoplasia grade 2: A prospective multicenter study in Italy.
Frayle H, Gori S, Pagan A, Soldà M, et al · · 2026 · cited 2× · PMID 40884232 · DOI 10.1002/ijc.70104
Verify or expand the search:
- PubMed search for NCT04687267
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for CIN2
Currently open trials in the same condition.
- NCT06147388 — Regression of Cervical Precancerous Lesions and Associated Risk Factors · recruiting
- NCT05027776 — Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years · Phase 3 · recruiting
- NCT04422366 — Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females · Phase 3 · recruiting
Other Istituto Oncologico Veneto IRCCS trials
Trials by the same sponsor.
- NCT07185568 — IntraOperative UltraSound Guided vs Wire Guided vs Magnetic Seed Guided Breast-Conserving Surgery for Non-palpable Tumor · NA · not yet recruiting
- NCT07338292 — VIrtual Reality Induced Pain and anxiEty Relief in Outpatient UROlogical Procedures · NA · recruiting
- NCT06753136 — Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histo · NA · recruiting
- NCT06595498 — Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung Cancer · NA · active not recruiting
- NCT06600568 — Novel Therapeutic Approach for Human T-cell Malignancies · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04687267 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istituto Oncologico Veneto IRCCS
- Last refreshed: 28 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04687267.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing